Heise, Tim
Stender-Petersen, Kirstine
Hövelmann, Ulrike
Jacobsen, Jacob Bonde
Nosek, Leszek
Zijlstra, Eric
Haahr, Hanne
Clinical trials referenced in this document:
Documents that mention this clinical trial
Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus
https://doi.org/10.1007/s40262-016-0473-5
Funding for this research was provided by:
Novo Nordisk
Article History
First Online: 22 November 2016
Compliance with Ethical Standards
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
: This study was funded by Novo Nordisk A/S.
: Tim Heise is shareholder of Profil, which received research funds from Adocia, AstraZeneca, Becton-Dickinson, Biocon, Boehringer Ingelheim, Dance Biopharm, Eli Lilly, Grünenthal, Gulf Pharmaceutical Industries, Johnson & Johnson, Marvel, MedImmune, Medtronic, Novartis, Novo Nordisk, Roche Diagnostics, Sanofi, Senseonics and Zealand Pharma. In addition, he is also a member of advisory panels for Novo Nordisk and received speaker honoraria and travel grants from Eli Lilly, Mylan and Novo Nordisk. Kirstine Stender-Petersen, Jacob Bonde Jacobsen and Hanne Haahr are employees and shareholders of Novo Nordisk. Eric Zijlstra received travel grants from Dance Biopharm and Novo Nordisk, and speaker honoraria from Novo Nordisk and Roche Diabetes Care. Ulrike Hövelmann and Leszek Nosek declare no conflicts of interest.